CLINICAL TRIAL: USE OF SILDENAFIL (VIAGRA) TO ALTER FATIGUE

临床试验：使用西地那非（伟哥）缓解疲劳

• 批准号: 8173587
• 负责人: THEODORE FRIEDMAN
• 金额: $ 8.36万
• 依托单位: CHARLES R. DREW UNIVERSITY OF MED & SCI
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8173587
• 关键词: Biological Markers; Brain; Cerebrovascular Circulation; Chronic; Chronic Fatigue Syndrome; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cyclic GMP; Defect; Diagnosis; Disease; Dizziness; Double-Blind Method; Failure; Fatigue; Funding; Grant; Impairment; Institution; Memory Loss; Monitor; Patients; Pharmaceutical Preparations; Placebos; Randomized; Research; Research Personnel; Resources; Scanning; Source; Testing; Therapeutic; United States National Institutes of Health; Viagra; functional status; indexing; inhibitor/antagonist; phosphoric diester hydrolase; placebo controlled study; response; sildenafil; single photon emission computed tomography; treatment duration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic Fatigue Syndrome (CFS) is a diabling condition characterized by chronic fatigue of at least 6 months duration an multiple somatic complaints, including memory loss, trouble concentrating and dizziness. The lack of a biological marker as well failure of any reproducible double-blind, placebo-control studies to demonstrate any therapeutic response makes CFS an extremely difficult disease to diagnose and treat. I hypothesize that some forms of CFS are due to inadequate cerebral blood flow resulting in the symptomatology seen in chronic fatigue symdrome including fatigue, dizziness and congitive impairment. This impaired cerebral blood flow would be visible as filling defects on brain SPECT scans. Appropriate treatment for CFS, therefore, would include agents which selectively increase cerebral blood flow. We propose that a directed approach to increase cerebral blood flow would be to use sildanifil (Viagra), an inhibitor of the type 5 cyclic guanosine monophosphate (cGMP) phosphodiesterase. Our objectives, therefore, are to test the following hypothesis: Patients with CFS treated with sildenafil are expected to have increased cerebral blood flow with an improvement of their fatigue and functional status as well as SPECT scan abnormalities. This hypothesis will be studied as follows: Patients will receive either sildenafil or placebo in a randomized, double-blind, placebo-controlled study for 6 weeks of active drug. Functional status, fatigue index, and brain SPECT scans will be monitored at baseline andd after each treatment period.

这个子项目是众多研究子项目之一